

To: 340B Covered Entity

From: Kevin Gray, Senior Vice President, Strategic Operations, United Therapeutics Corporation

Dated: April 8, 2022

Subject: United Therapeutics Corporation 340B Contract Pharmacy Policy—Special Enrollment Period for Claims Data Requirement

Dear 340B Covered Entity:

United Therapeutics Corporation (“UT”) previously announced its contract pharmacy policy (the “Policy”),¹ which includes a claims data reporting requirement that became effective December 1, 2021.

UT understands that certain Covered Entity stakeholder groups have misconstrued the scope of manufacturer obligations regarding 340B contract pharmacy orders, which may have caused covered entities to take certain positions regarding the claims data requirement. ***UT therefore is providing covered entities that comply with the other aspects of the Policy, but that to date have not complied with the claims data reporting requirement, the opportunity to submit a request to prospectively comply with the claims data requirement, beginning July 1, 2022.***

Under the Policy, UT provides 340B-discounted pricing for certain of our covered outpatient drugs ordered through contract pharmacies if both of the following apply:

- First, the contract pharmacy was utilized by the covered entity for a valid 340B purchase of a UT covered outpatient drug subject to the Policy during the first three full quarters of the 2020 calendar year (i.e., January 1 through September 30, 2020); and
- Second, the covered entity has agreed to provide, and is providing on an ongoing basis, specified claims data associated with all 340B contract pharmacy orders of UT’s covered outpatient drugs subject to the Policy via a platform hosted by a third party with appropriate security and patient privacy safeguards (available at www.340BESP.com).

We are reaching out to you because your covered entity complied with the first requirement of the Policy, but to date has not complied with the claims data requirement. UT, as a courtesy and in its sole discretion, is offering your covered entity the opportunity to request prospective eligibility under the Policy, beginning July 1, **2022**.

In order to submit a request, contact 340B@unither.com **no later than May 31, 2022**. Requests received after that date will not be considered.

¹ See UT’s letters of November 18, 2020, April 12, 2021, May 11, 2021, and July 23, 2021, which were sent to you previously. As communicated in these letters, the Policy does not apply to ADCIRCA (tadalafil) and is subject to further conditions and exceptions, and UT may revise the Policy at its sole discretion at any time and without prior notice.



P.O. Box 14186
55 T.W. Alexander Drive
Research Triangle Park, NC 27709
tel 919.485.8350
fax 919.485.8352

Prospective eligibility for 340B contract pharmacy ordering may be granted by UT, in its sole discretion, on the conditions that: a) your covered entity satisfies all existing requirements of the Policy, and b) that by June 30, 2022 your covered entity submits an attestation, in the form and manner provided by UT, as to compliance with all requirements of the Policy and acknowledging that your covered entity's eligibility for 340B contract pharmacy ordering for subject covered outpatient drugs under the Policy will only apply prospectively to subject covered outpatient drugs dispensed on or after July 1, 2022.

For questions regarding the Policy or this special enrollment period, please contact UT at 340b@unither.com.